Advancing Regulatory Pathways for Complex In Vitro Models to Enhance Predictive Toxicity Assessments

  • Establishing evidentiary considerations for model validation and qualification to align with global health authority requirements and standards
  • Identifying context of use and unmet needs for complex in vitro models to address near-term regulatory applications
  • Integrating models throughout pharmaceutical pipelines from high-throughput screening to IND applications to accelerate development timelines